Physician profile
Adnan I Khan
NPI 1649539172
$3,304.01
in general payments reported to CMS, 2019-2025
33 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2020: $694 · 2021: $1,313 · 2022: $23.58 · 2023: $130 · 2024: $326 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $577 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.80 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $707.72 | 2021-2025 | |
| Allergan, INC. | $437.69 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $278.50 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $241.30 | 2021 | |
| Genzyme Corporation | $218.74 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $148.49 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $135.47 | 2019-2020 | |
| Eisai INC. | $99.35 | 2020-2023 | |
| Jazz Pharmaceuticals INC. | $92.47 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $89.72 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $88.39 | 2019 | |
| Corium, LLC | $72.95 | 2021 | |
| Amgen INC. | $70.76 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $58.69 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.99 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $50.06 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $42.97 | 2019-2021 | |
| Lundbeck LLC | $38.72 | 2021 | |
| Ge Healthcare | $38.48 | 2019-2020 | |
| Shire North American Group INC | $38.43 | 2019 | |
| Neos Therapeutics, LP | $36.52 | 2019 | |
| Ucb, INC. | $33.86 | 2019-2021 | |
| Biogen, INC. | $32.95 | 2019-2021 | |
| Bausch Health US, LLC | $31.69 | 2021 | |
| Arbor Pharmaceuticals, INC. | $27.34 | 2019-2021 | |
| Adlon Therapeutics L.P. | $26.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.25 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $20.16 | 2019 | |
| Livanova USA, INC. | $13.96 | 2019 | |
| Tris Pharma INC | $13.85 | 2019 | |
| Merck Sharp & Dohme LLC | $13.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.18 | 2020 | |
| Almatica Pharma LLC | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.